Capstan Medical develops technology for the treatment of structural heart disease by combining surgical robotics with catheter-based technology and next generation implants to repair and replace heart valves.

Capstan Medical

At Capstan Medical, we’re driven by an unwavering commitment to transforming the treatment of structural heart disease. By merging surgical robotics with catheter-based technology and next generation implants, we’ve pioneered a patient-optimized approach to repair and replace heart valves.

Heart disease continues to be a leading cause of death in the U.S., claiming the lives of nearly 700,000 Americans each year.

Although many cardiovascular treatments have improved and become less invasive, there are still procedures that need improvements. Innovation in this space continues to unfold, promising even better outcomes, faster recovery, and less invasive procedures.

In this LSI USA ‘24 panel, we heard from innovators who are building in this space, and the strategics and investors who have dedicated decades to advancing this field. Together they share recent advances, emerging trends, and the investment landscape fueling these innovations.

Featured Panelists:
• JD Friedland (Moderator), Managing Director, Ventures, Cleveland Clinic
• Maggie Nixon, CEO, Capstan Medical
• Donald E Bobo Jr, Corporate VP, Edwards Lifesciences
• Jacques Essinger, CEO, Polares Medical
• William Phillips, Founder & Managing Partner, Alruna Advisors

The full panel, “Structural Heart Innovation in Medtech's Era of Change” is available on our website and YouTube channel.

Capstan Medical's Social Summer Fun! One (of MANY) benefits to being located in Santa Cruz is access to the beach! The team has gathered together for BBQ's, intern socials, beach bonfires, and of course tie-dying to equip us for our weekly Tie-Dye Tuesday!

Great recap Chris! Glad you liked hearing what Capstan Medical is up to!

Day One in the books for #SRS2024. 

Outstanding day. 

Steve Bell opened up and shared his thoughts and insights that was based on evidence and trends as to where the surgical robotic market in heading.

Dave Rosa from Intuitive as usual was insightful, candid and transparent. As transparent as a publicly traded company can be. Refreshing, given some of the other circle-talking that occurs from other public companies that are here.

The investor panel is always enlightening. As well as revealing as to what are the investors NOT talking about. 

I was surprised that no time was given to the rapidly changing centers of care and how that will greatly influence the entire market from form factors, pricing, investments, sales forces, etc.

The debate around the details of the path over the period of the next 2-5 years would be fair.

- Do 30%? 50%? 75% of procedures convert to robotics?
- What verticals will emerge and adopt at a greater rate than others?
- What companies will lead in each category?
- Where will the procedures take place?
- What does the pricing model look like?
- Are the systems straight up purchased? Price per Procedure? Surgery as a Service?

Debate away

But stepping out over the next 15-20 years, those debate points become irrelevant and moot.

Surgical robotics will be the rule and not the exception.
The definition of "surgical robotics" will also evolve.

A finer stratification of robots, patient selection, sites of care will create great companies and careers.

Companies that are not even born yet will likely dominate a good number percentage of surgical robotic verticals.

Dragonfly - A TMG Company had our full field studio on site, right in the middle of the mosh pit.

Thanks to 
Maggie Nixon from Capstan Medical
Pedro Costa from Interventional Systems
Scott Huennekens and Ben Lundgren from On Target Laboratories

And to Anne Osdoit and Jeffery Alvarez from Moon Surgical for the reveal of the Maestro on Wheels ribbon cutting.

See you at Day 2.

So exciting to see lots of amazing things happening in robotic surgery at #SRS2024. It was a privilege to have our CEO Maggie Nixon be on a panel with so may impactful up and coming robotically enabled technologies!

On May 8th, Jim Hammerand of Medical Design and Outsourcing interviewed Capstan Medical's CEO Maggie Nixon. Check out the article here: https://lnkd.in/g8tyD_9t

Capstan Medical's CEO Maggie Nixon was honored to participate in LSI's structural heart innovation panel alongside such great leaders in the field: JD Friedland, Donald E Bobo Jr, Jacques Essinger, and William Phillips. Looking forward to continuing the conversation as we all strive to transform the available treatments for structural heart disease!

Capstan Medical is excited to kick off the new year by announcing our newly established Clinical Advisory Board: Dr. Mark Webster at University of Auckland and Auckland City Hospital, Dr. Charanjit (Chet) Rihal at Mayo Clinic and Dr. Gorav Ailawadi, MD, MBA at University of Michigan. Strong collaboration between doctors and engineers is powerful fuel for groundbreaking innovation. These clinicians bring a depth of experience and skill that is unparalleled and we are thrilled to welcome them to the Capstan team!

Capstan Medical just wrapped up their very first Tech Suite at the TCT conference!  It was amazing to share the Capstan Medical vision and technology with clinicians, investors and key suppliers alike. A fantastic week of learning and building partnerships to create a new standard for structural heart intervention.  Onward!

Metric
Company Name	Capstan Medical
Symbol
MSH ID	COM:CAPSTANMEDICAL
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Devices
Country	US
Stage
Employee Count
Website	capstanmedical.com
LinkedIn	capstanmedical
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CAPS

COM:CAPSTANMEDICAL

Capstan Medical

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue